Policy & Regulation
Akeso initiates Phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer
20 August 2025 - China-based biopharmaceutical company Akeso, Inc. (HKG:9926) on Wednesday announced that the first patient has been enrolled and dosed in its Phase III clinical trial, COMPASSION-33, ...
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
20 August 2025 - Oncology company Novocure (NASDAQ: NVCR) announced on Wednesday that it has submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Tum...
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
20 August 2025 - Biotechnology company Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its pivotal Pha...
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
20 August 2025 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Wednesday that it has completed patient enrollment for SANOVO, its China Phase III ...
Abbvie completes Capstan Therapeutics acquisition
20 August 2025 - US pharmaceutical company AbbVie (NYSE: ABBV) confirmed on Tuesday that it has completed its acquisition of biotechnology company Capstan Therapeutics.As a result, Capstan is now part...
Viking Therapeutics reports positive top-line results from Phase 2 trial of VK2735 oral tablet
20 August 2025 - Viking Therapeutics Inc (NASDAQ:VKTX), a US clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced on ...